Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Cost-effectiveness threshold (health economics)
The ceiling incremental cost-effectiveness ratio (ICER) beyond which interventions are no longer considered cost effective, reflecting the maximum value decision makers attach to health benefits. This may be stated in terms of cost per quality adjusted life year (QALY) gained.
See also:
Decision making unit (DMU)
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-minimisation analysis (CMA)
Cost consequences analysis (CCA)
Related terms
Secondary care, Economic regulation, Cost-effectiveness league table (healthcare economics), Utility weighted index, Quality-adjusted life year (QALY), Standard treatment, Sensitivity to change (pharmacoeconomics), Concordance, Payback period, Foundation Trust (FT), Competitors, Department of Health (DH), Preferred provider organisation (PPO), National Institute for Health and Clinical Excellence (NICE), Quality assurance programme,
Featured jobs
-
Vice President
-
Competitive Salary Offered
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Consultant
-
competitive salary
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
Subscribe to our email news alerts
- New coronavirus sees drug developers scramble to develop a vaccine
- Moving annual total (MAT)
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- NICE knocks back AstraZeneca's Tagrisso again
- Immuno-oncology, personalised medicine continues to drive pharma sector
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Data desires
- TBWA\WorldHealth London announces restructure and key hires
- WHITE PAPER: Marketing fulfilment – a balancing act
- AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer
- Roche files Tecentriq/Avastin combo in liver cancer
- New coronavirus sees drug developers scramble to develop a vaccine
PMHub
Frontera Group
Welcome to Frontera Group, where our agencies immerse you in the world of the patient...
Quick links
Infographics
